Edmundo J N Camara1, Vitor R R Mendonca2, Ligia C L Souza2, Juliana S Carvalho3, Ruda A Lessa4, Ramon Gatto4, Luan O Barreto4, Giulianna Chiacchio4, Eduardo Amarante3, Monaliza Cunha5, Luis S Alves-Silva5, Benelson A C Guimarães6, Manoel Barral-Netto7. 1. Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil; Unidade Docente Assistencial de Cardiologia (UDAC), Complexo Hospitalar Professor Edgard Santos Universidade Federal da Bahia, Salvador, Brazil. 2. Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Brazil; Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil. 3. Faculdade de Tecnologia e Ciências, Salvador, Brazil. 4. Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil. 5. Unidade Docente Assistencial de Cardiologia (UDAC), Complexo Hospitalar Professor Edgard Santos Universidade Federal da Bahia, Salvador, Brazil. 6. Climecar, Clinica de Cardiologia, Itaberaba, Bahia, Brazil. 7. Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Brazil; Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil; Instituto Nacional de Ciência e Tecnologia em Investigação em Imunologia (iii-INCT), São Paulo, Brazil. Electronic address: manoel.barral@gmail.com.
Abstract
BACKGROUND: The immunological and clinical impact of trypanocidal treatment in chronic Chagas' disease (CCD) is unclear. METHODOLOGY AND FINDINGS: Several cytokines were measured in plasma of 66 patients with CCD. Thirty-three patients had been previously treated with benznidazole and 33 had never been treated. The treated group exhibited higher levels of IL-17 (median 142.45×1.22pg/ml, P=0.025), which was the only one significantly associated with Bz treatment, especially after adjusting for time of disease and NYHA class (P=0.024; OR 1.006, 95% CI 1.001-1.010). Compared to untreated patients, the treated group exhibited higher median values of mitral annular E' lateral (13.0×10.0cm/s, P=0.038), S' infero-lateral (8.9×7.6cm/s, P=0.013), S' septal (8.5×7.4cm/s, P=0.034), mean S' (9.0×7.9cm/s, P=0.013) and tricuspid annular S' (13.3×11.1cm/s, P=0.001) and lower values of E/E' septal (7.2×9.5cm/s, P=0.049). After adjustment for time of disease and NYHA class, S' infero-lateral (P=0.031), mean S' (P=0.049) and S' tricuspid (P=0.024) persisted as significantly associated with treatment. CONCLUSION: The present findings suggest that the group of CCD patients treated with Bz displayed increased plasma levels of IL-17 and preserved myocardial function, reinforcing the idea that Bz treatment may be beneficial.
BACKGROUND: The immunological and clinical impact of trypanocidal treatment in chronic Chagas' disease (CCD) is unclear. METHODOLOGY AND FINDINGS: Several cytokines were measured in plasma of 66 patients with CCD. Thirty-three patients had been previously treated with benznidazole and 33 had never been treated. The treated group exhibited higher levels of IL-17 (median 142.45×1.22pg/ml, P=0.025), which was the only one significantly associated with Bz treatment, especially after adjusting for time of disease and NYHA class (P=0.024; OR 1.006, 95% CI 1.001-1.010). Compared to untreated patients, the treated group exhibited higher median values of mitral annular E' lateral (13.0×10.0cm/s, P=0.038), S' infero-lateral (8.9×7.6cm/s, P=0.013), S' septal (8.5×7.4cm/s, P=0.034), mean S' (9.0×7.9cm/s, P=0.013) and tricuspid annular S' (13.3×11.1cm/s, P=0.001) and lower values of E/E' septal (7.2×9.5cm/s, P=0.049). After adjustment for time of disease and NYHA class, S' infero-lateral (P=0.031), mean S' (P=0.049) and S' tricuspid (P=0.024) persisted as significantly associated with treatment. CONCLUSION: The present findings suggest that the group of CCDpatients treated with Bz displayed increased plasma levels of IL-17 and preserved myocardial function, reinforcing the idea that Bz treatment may be beneficial.
Authors: Andrés Sanchez Alberti; Augusto E Bivona; Marina N Matos; Natacha Cerny; Kai Schulze; Sebastian Weißmann; Thomas Ebensen; Germán González; Celina Morales; Alejandro C Cardoso; Silvia I Cazorla; Carlos A Guzmán; Emilio L Malchiodi Journal: Front Immunol Date: 2020-02-21 Impact factor: 7.561
Authors: Renata Watanabe Costa; Marina Ferreira Batista; Isabela Meneghelli; Ramon Oliveira Vidal; Carlos Alcides Nájera; Ana Clara Mendes; Izabela Augusta Andrade-Lima; José Franco da Silveira; Luciano Rodrigo Lopes; Ludmila Rodrigues Pinto Ferreira; Fernando Antoneli; Diana Bahia Journal: Front Immunol Date: 2020-08-27 Impact factor: 7.561